Home > Insider Trading > Filing (0000950170-25-093907)

Filing Details

Accession Number:: 0000950170-25-093907
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2025-07-03 16:30:19
Reporting Period:: 2025-07-01

Filing Date:: 2025-07-03
Accepted Time:: 2025-07-03 16:30:19
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1743881	Bridgebio Pharma Inc.	BBIO	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1742485	Neil Kumar	C/O Bridgebio Pharma, Inc. 3160 Porter Dr., Suite 250 Palo Alto CA 94304	Chief Executive Officer	No	No	No	No

Transaction Summary

Sold:	80,000 shares	Avg. Price: $42.63	Total Value: $3,410,450.42
Number of Shares After Transactions:	955,686 shares

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2025-07-01	18,300	$42.50	4,780,147	No	4	S	Indirect	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.
Common Stock	Disposition	2025-07-01	1,700	$42.88	4,778,447	No	4	S	Indirect	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.
Common Stock	Disposition	2025-07-02	20,000	$42.73	4,758,447	No	4	S	Indirect	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.
Common Stock	Disposition	2025-07-01	18,400	$42.51	977,286	No	4	S	Indirect	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.
Common Stock	Disposition	2025-07-01	1,600	$42.89	975,686	No	4	S	Indirect	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.
Common Stock	Disposition	2025-07-02	20,000	$42.73	955,686	No	4	S	Indirect	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.
No	4	S	Indirect	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.
No	4	S	Indirect	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.
No	4	S	Indirect	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.
No	4	S	Indirect	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.
No	4	S	Indirect	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	217,404	Direct

Footnotes

This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024.
Represents the weighted average sale price of the shares sold from $41.80 to $42.79 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
Represents the weighted average sale price of the shares sold from $42.81 to $42.96 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
Represents the weighted average sale price of the shares sold from $42.145 to $43.10 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
Represents the weighted average sale price of the shares sold from $41.81 to $42.80 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
Represents the weighted average sale price of the shares sold from $42.81 to $42.98 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
Represents the weighted average sale price of the shares sold from $42.22 to $43.10 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.